Publications
5677 Results
- Journal / Conference
- JAMA Network Open Oct 1;7(10):e2437871
- Year
- 2024
- Research Committee(s)
- Genitourinary
- PMID
- PMID39374015
- PMC
- PMC11581504
- Study Number(s)
- S1216
Circulating tumor cell (CTC) count is prognostic of overall survival in metastatic hormone sensitive prostate cancer (mHSPC)
- Journal / Conference
- Clinical Cancer Research Oct 17. doi: 10.1158/1078-0432.CCR-24-0606. Online ahead of print
- Year
- 2024
- Research Committee(s)
- Early Therapeutics and Rare Cancers
- PMID
- PMID39417692
- Study Number(s)
- S1609
SWOG/NCI S1609 Phase II Basket Trial Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART): Non-Epithelial Ovarian Cancer
- Journal / Conference
- JCO Precision Oncology Nov:8:e2400287. doi: 10.1200/PO.24.00287. Epub 2024 Nov 5. 2024
- Year
- 2024
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S1314
DNA Damage Response Gene Alterations Predict for Neoadjuvant Chemotherapy Sensitivity in Muscle-Invasive Bladder Cancer: A Correlative Analysis of the SWOG S1314 Trial
- Journal / Conference
- ICTHIC Meeting (May 17-19, 2024, Bergamo, Italy)
- Year
- 2024
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- CTSU/C80405
Navigating the Interplay of Cancer, Hemostasis, and Thrombosis: Investigating Tissue Factor in Colorectal Cancer
- Journal / Conference
- Journal of Clinical Oncology Dec 2:JCO2401507. doi: 10.1200/JCO-24-01507. Online ahead of print
- Year
- 2024
- Research Committee(s)
- Breast
- PMID
- PMID39621968
- Study Number(s)
- S1007, SWOG-8814
Development and validation of the RSClinN+ tool that integrates the 21-gene recurrence score and clinical variables to predict prognosis and chemotherapy benefit for hormone receptor-positive (HR+), HER2-negative (HER2-), node-positive breast cancer
- Journal / Conference
- JAMA Oncology Nov 7;10(12):1654-1662
- Year
- 2024
- Research Committee(s)
- Cancer Control, Prevention, Screening, and and Surveillance
- PMID
- PMID39509091
- PMC
- PMC11544550
- Study Number(s)
- S0000, SWOG-9217
Long-term side effects and complications after prostate cancer treatment
- Journal / Conference
- Society of Thoracic Surgeons (STS) (Jan 27-29, 2024, San Antonio, TX)
- Year
- 2024
- Research Committee(s)
- Lung
Association Between Surgical Margin Distance, Locoregional Recurrence, and Survival Among Patients Undergoing Sublobar Resection in CALGB 140503 (Alliance)
- Journal / Conference
- Therapeutic Advances in Medical Oncology Nov 22:16:17588359241293401
- Year
- 2024
- Research Committee(s)
- Early Therapeutics and Rare Cancers
- PMID
- PMID39583952
- PMC
- PMC11583498
- Study Number(s)
- S1609
Phase II Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG/NCI Experience: Invasive Mucinous or Non-mucinous Lepidic Adenocarcinoma of the Lung (Formerly Bronchioloalveolar Carcinoma)
- Journal / Conference
- Association for Molecular Pathology (November 14-18, 2024, Salt Lake City, UT), poster
- Year
- 2024
- Research Committee(s)
- Leukemia
- Study Number(s)
- S0106
Next-generation cytogenomics using proximity ligation technology on the AVITI genome sequencing platform
- Journal / Conference
- Contemporary Clinical Trials Dec:147:107712
- Year
- 2024
- Research Committee(s)
- Symptom Management and Survivorship
- PMID
- PMID39395534
- PMC
- PMC11620912
- Study Number(s)
- S2010